Why ARNT Prostate Tumors Responding to Enzalutamide?

Cancer Discov. 2022 Sep 2;12(9):2017-2019. doi: 10.1158/2159-8290.CD-22-0702.

Abstract

Prostate tumors can develop resistance to androgen receptor (AR)-targeted therapies through treatment-induced changes in transcription factor activity that promote transcriptional and morphologic features of a neuroendocrine lineage. This study identifies an unexpected role for the circadian protein ARNTL in resistance to enzalutamide, a second-generation AR-targeted therapy. See related article by Linder et al., p. 2074 (4).

Trial registration: ClinicalTrials.gov NCT03297385.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Androgens*
  • Aryl Hydrocarbon Receptor Nuclear Translocator
  • Benzamides
  • Circadian Rhythm
  • Drug Resistance, Neoplasm / genetics
  • Epigenomics
  • Humans
  • Male
  • Nitriles
  • Phenylthiohydantoin
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / genetics
  • Prostatic Neoplasms, Castration-Resistant* / metabolism
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism

Substances

  • ARNT protein, human
  • Androgens
  • Benzamides
  • Nitriles
  • Receptors, Androgen
  • Aryl Hydrocarbon Receptor Nuclear Translocator
  • Phenylthiohydantoin
  • enzalutamide

Associated data

  • ClinicalTrials.gov/NCT03297385